chiron (represented by Critical Mass Beteiligungs UG)

chiron advances microfluidic technologies to help pharma and biotech innovators gain human-relevant insights before preclinical testing or clinical trials. Our leading technologies, Re-plate and μMass, use primary, human cells to deliver predictive, human-relevant data. Re-plate recreates human-like movement in-vitro to better recapitulate healthy and diseased states of tissue. μMass is the go-to solution for the robust creation and culturing of 3D solid-tumour aggregates, organoids, spheroids.